How a French Chemical Company Resolved a Royalty Withholding Tax Dispute in China: Technology Licensing Case Study

Executive Summary

In 2022, a French specialty chemical company headquartered in Lyon, France, found itself in a protracted dispute with the Chinese tax authorities over the application of withholding tax to royalty payments received under a technology licensing agreement with its Chinese subsidiary. The company, referred to here as ChemFrance SAS, had entered into a technology licensing agreement with its wholly foreign-owned enterprise (WFOE) subsidiary in Shanghai in 2018, under which the WFOE paid royalties for the use of ChemFrance’s proprietary polymer synthesis technology and associated trademarks. Over the course of four years, the Shanghai tax bureau assessed additional withholding tax, late payment surcharges, and penalties totaling approximately EUR 3.8 million, asserting that the royalty rate exceeded arm’s length standards and that the licensed technology did not qualify for certain tax treaty benefits claimed by ChemFrance under the France-China Double Taxation Agreement.

This case study examines the legal, commercial, and strategic dimensions of the withholding tax dispute, including the application of China’s Enterprise Income Tax (EIT) Law and its implementing regulations, the interpretation of the France-China tax treaty provisions on royalty taxation, the transfer pricing documentation requirements for related-party technology licensing transactions, and the dispute resolution mechanisms available to foreign licensors. The dispute was ultimately resolved through a combination of administrative reconsideration, mutual agreement procedure (MAP) under the tax treaty, and a restructuring of the licensing agreement to address the tax authorities’ concerns, resulting in a reduction of the total tax assessment from EUR 3.8 million to EUR 1.2 million.

The Licensing Agreement and Tax Treatment

Technology and Commercial Background

ChemFrance SAS was a mid-sized specialty chemical company with approximately 850 employees and annual revenues of approximately EUR 420 million. The company’s core technology was a proprietary catalytic polymerization process for producing high-performance polymer additives used in automotive coatings, industrial adhesives, and consumer electronics encapsulation materials. The technology had been developed over 15 years at ChemFrance’s R&D center in Lyon, resulting in 28 active patent families and substantial proprietary know-how related to catalyst preparation, reaction condition optimization, and quality control methodologies.

The Shanghai WFOE, established in 2015, served as ChemFrance’s manufacturing and distribution hub for the Chinese market. The WFOE’s manufacturing facility in the Shanghai Chemical Industry Park produced approximately 12,000 metric tons of specialty polymer additives per year, generating annual revenues of approximately CNY 580 million (approximately EUR 75 million). The WFOE was a separate legal entity under Chinese law but was wholly owned by ChemFrance SAS and functioned as an integral part of ChemFrance’s global production network.

The Licensing Agreement Structure

The technology licensing agreement between ChemFrance SAS (licensor) and the Shanghai WFOE (licensee), executed in 2018 and effective from January 1, 2019, granted the WFOE a non-exclusive, non-transferable license to use ChemFrance’s proprietary polymerization technology and associated trademarks for the manufacture and sale of specialty polymer additives in China. The royalty rate was set at 5 percent of net sales of products manufactured using the licensed technology, which was within the range observed in comparable third-party licensing transactions in the specialty chemicals industry globally. Annual royalty payments averaged approximately EUR 3.2 million over the 2019-2021 period.

Under the China-France Double Taxation Agreement (signed in 1984, amended by protocol in 2013), royalties arising in China and beneficially owned by a French resident are subject to withholding tax at a rate of 10 percent of the gross amount of the royalties, provided that the French resident is the beneficial owner of the royalties and does not have a permanent establishment in China to which the royalties are effectively connected. ChemFrance SAS applied the 10 percent treaty rate when remitting royalty payments from the WFOE to France, withholding and remitting the tax to the Chinese tax authorities on behalf of the WFOE under China’s domestic withholding tax rules for outbound payments.

The Tax Dispute: Trigger and Evolution

Tax Audit Initiation

In March 2022, the Shanghai Tax Service, State Taxation Administration (STA), initiated a transfer pricing audit of the Shanghai WFOE’s related-party transactions for the 2019-2021 tax years. The audit was part of a broader initiative by the STA to scrutinize royalty payments from Chinese subsidiaries to foreign parent companies, particularly in the chemical, pharmaceutical, and technology sectors, where the STA believed that royalty rates were frequently inflated to shift profits out of China. The tax authorities requested comprehensive documentation, including the technology licensing agreement, valuations of the licensed technology, transfer pricing documentation (contemporaneous documentation as required under Circular 16 of the STA), financial statements of both the Chinese WFOE and the French parent, and evidence of the economic substance and value creation activities of the French licensor.

ChemFrance SAS and the WFOE engaged a Big Four accounting firm’s transfer pricing practice in Shanghai to assist with the audit response. The initial response package included a transfer pricing benchmark study demonstrating that the 5 percent royalty rate fell within the interquartile range of 3.2 percent to 6.8 percent for comparable specialty chemical licensing transactions, a technology valuation report prepared by an independent valuation firm confirming that the licensed technology had a fair value supporting the royalty rate, and evidence of ChemFrance’s continued R&D activities in France that supported the beneficial ownership claim under the tax treaty.

The Tax Bureau’s Position

After reviewing the documentation, the Shanghai tax bureau issued a preliminary assessment in July 2022 challenging the royalty arrangement on three grounds. First, the tax authorities asserted that the 5 percent royalty rate exceeded arm’s length standards for related-party technology licensing transactions in the Chinese specialty chemical industry, citing an internal benchmarking study that suggested a median royalty rate of 2.8 percent for comparable transactions. The benchmark study used by the tax authorities was based on a different set of comparable transactions than ChemFrance’s study, leading to a significant divergence in the arm’s length range.

Second, the tax authorities argued that the licensed technology had substantially depreciated in value by the time of the audit period because the core patents were approaching expiration and the related know-how had been largely transferred to the WFOE’s Chinese employees during the initial technology transfer in 2018-2019. The tax authorities took the position that the post-transfer know-how maintenance and updates provided by ChemFrance SAS did not constitute new technology contributions that would support continued royalty payments at the original rate.

Third, the tax authorities challenged ChemFrance’s claim to the reduced 10 percent withholding tax rate under the France-China tax treaty, asserting that ChemFrance SAS did not qualify as the “beneficial owner” of the royalties within the meaning of Article 12 of the treaty. The tax authorities applied the beneficial ownership test developed under the STA’s Circular 9 (2018) and the OECD’s Base Erosion and Profit Shifting (BEPS) Action 6 recommendations, concluding that ChemFrance SAS lacked the economic substance and decision-making authority over the licensed technology to qualify as the beneficial owner of the royalty income.

Dispute Resolution Process

Administrative Reconsideration

ChemFrance and its WFOE filed an administrative reconsideration application with the Shanghai Municipal Tax Service in September 2022, requesting a review of the preliminary assessment. The administrative reconsideration process under China’s Tax Collection and Administration Law allows taxpayers to request a review of tax assessments by the next-higher-level tax authority. The application included a detailed legal analysis of the beneficial ownership issue, arguing that ChemFrance SAS met all four criteria for beneficial ownership under Circular 9: the company had the right to use and enjoy the licensed technology, it assumed the economic risks associated with the technology ownership, it had control over the technology’s exploitation decisions, and it derived substantive economic benefit from the royalty income.

The Shanghai Municipal Tax Service issued its reconsideration decision in December 2022, upholding the preliminary assessment on all three grounds. The reconsideration decision represented the exhaustion of the domestic administrative remedies available to ChemFrance, leaving the company with the choice of either accepting the assessment and paying the tax, surcharges, and penalties totaling EUR 3.8 million, or pursuing further remedies through the Mutual Agreement Procedure under the France-China tax treaty or through Chinese administrative litigation.

Mutual Agreement Procedure (MAP)

ChemFrance SAS elected to pursue a Mutual Agreement Procedure (MAP) application under Article 25 of the France-China Double Taxation Agreement. The MAP allows a resident of a contracting state who considers that the actions of one or both contracting states result in taxation not in accordance with the treaty to present the case to the competent authority of the state of which the taxpayer is a resident. ChemFrance’s MAP application was submitted to the French tax authorities (Direction Generale des Finances Publiques, DGFiP) in January 2023, requesting that the DGFiP engage with the STA to resolve the disputed tax treatment.

The MAP application included a comprehensive legal analysis demonstrating that the Shanghai tax bureau’s assessment resulted in taxation that was not in accordance with the France-China tax treaty, specifically Article 12 (Royalties) and Article 25 (Mutual Agreement Procedure). ChemFrance argued that the denial of treaty benefits violated the nondiscrimination provisions of the treaty and that the transfer pricing adjustment exceeded the scope of adjustments permitted under the arm’s length principle as articulated in the OECD Transfer Pricing Guidelines and China’s own transfer pricing regulations.

The MAP process involved a series of bilateral consultations between the DGFiP and the STA, conducted through diplomatic channels and technical working group meetings, over a period of approximately 14 months. The MAP concluded in March 2024 with a mutual agreement that resolved the dispute on the following terms: the royalty rate of 5 percent was accepted as arm’s length for the period 2019-2022, subject to a prospective adjustment to 4 percent for the remaining license term (2023-2027); the beneficial ownership claim was accepted, confirming ChemFrance’s entitlement to the 10 percent treaty rate; and late payment surcharges were reduced from EUR 1.1 million to EUR 0.3 million, representing a concession by the tax authorities in recognition of the good faith nature of the dispute.

Restructuring the Licensing Agreement

Prospective Adjustments

As part of the MAP resolution, ChemFrance SAS agreed to restructure the licensing agreement to address the tax authorities’ concerns about technology value depreciation and the ongoing economic substance of the royalty payments. The restructuring involved three key changes. First, the royalty rate was prospectively reduced from 5 percent to 4 percent of net sales for the period 2023-2027, reflecting the tax authorities’ view that the technology’s value had diminished as the core patents approached expiration. Second, the royalty base was modified to exclude sales of products that no longer relied on the licensed patents, applying a patent dependency ratio methodology that the tax authorities had accepted in previous cases involving other chemical companies.

Third, a technology update and R&D contribution schedule was incorporated into the restructured agreement, requiring ChemFrance to document and quantify the annual R&D contributions from the French operations that supported the continued value of the licensed technology. The schedule required an annual report to be submitted to the Shanghai WFOE (and available for tax audit purposes) describing the new patents filed, process improvements developed, and technical support activities conducted during each calendar year. This documentation provided contemporaneous evidence of the ongoing technology contributions that supported the continued royalty payments.

Transfer Pricing Documentation Enhancement

Beyond the restructuring of the licensing agreement itself, ChemFrance and its Shanghai WFOE implemented a comprehensive transfer pricing documentation enhancement program. The program included the preparation of a master file (covering ChemFrance’s global business operations, value chain, and transfer pricing policies), a local file (covering the Shanghai WFOE’s operations, functional analysis, and related-party transactions), and a country-by-country report (covering the global allocation of income, taxes, and business activities). The master file and local file were prepared in accordance with the documentation requirements under Chapter 6 of China’s Implementation Measures for Special Tax Adjustments (Circular 42), which imposes stringent contemporaneous documentation requirements for related-party technology licensing transactions exceeding CNY 50 million annually.

The enhanced documentation also included a biennial benchmarking study that updated the arm’s length analysis of the royalty rate, ensuring that the rate remained within the acceptable range as market conditions and industry practices evolved. The first updated benchmarking study, completed in 2024, confirmed that the revised 4 percent royalty rate remained within the arm’s length range of 2.5 percent to 5.8 percent for the specialty chemical licensing comparables.

Strategic Implications and Lessons

Tax Risk Management for Technology Licensing in China

The ChemFrance case highlights the importance of proactive tax risk management for foreign companies licensing technology to related parties in China. The transfer pricing audit was initiated as part of a broader enforcement trend by the Chinese tax authorities, who have significantly increased their scrutiny of outbound royalty payments since 2019. Foreign licensors should anticipate that their related-party licensing agreements will be subject to audit and should prepare their documentation accordingly, with particular attention to the three key risk areas identified in the ChemFrance case: the arm’s length nature of the royalty rate, the economic substance of the technology contributions supporting continued royalty payments after the initial technology transfer, and the beneficial ownership analysis required for treaty rate claims.

Companies should also be aware that the administrative reconsideration process, while a necessary prerequisite for MAP and litigation, is unlikely to produce a favorable outcome in transfer pricing disputes. The reconsideration is conducted by the same tax authority hierarchy that issued the original assessment, and the rate of taxpayer success in administrative reconsideration for transfer pricing cases is extremely low. The MAP process, while resource-intensive, provides a more balanced forum for resolving disputes because it involves negotiation between two sovereign tax authorities, each with an interest in reaching a principled resolution that protects its own tax base while respecting treaty obligations.

Practical Recommendations for Royalty Agreement Structures

Based on the ChemFrance experience, several practical recommendations emerge for foreign companies structuring technology licensing agreements with Chinese related parties. The royalty rate should be supported by a robust transfer pricing benchmark study prepared by a qualified firm familiar with the customs and practices of the Chinese tax authorities, not merely a study prepared for general OECD compliance purposes. The benchmarking analysis should use comparables that reflect the specific characteristics of the Chinese market, including the availability of alternative technologies from Chinese suppliers and the unique regulatory environment for technology licensing in China.

The licensing agreement should clearly document the ongoing technology contributions that support continued royalty payments beyond the initial technology transfer period. This documentation should include a schedule of anticipated R&D activities, a description of the process improvement and technical support services to be provided, and a mechanism for updating the technology documentation and transferring improvements to the Chinese licensee. The agreement should also include provisions for adjusting the royalty rate over time as the technology matures, patents expire, and market conditions evolve, which can serve as evidence that the parties have considered the technology lifecycle in establishing the royalty structure.

Conclusion

The ChemFrance withholding tax dispute demonstrates that royalty taxation in China has become a complex and high-stakes area of regulatory compliance for foreign technology licensors. The evolving enforcement practices of the Chinese tax authorities, combined with the increasingly sophisticated application of transfer pricing principles and beneficial ownership analysis, require foreign companies to invest significantly in documentation, compliance, and proactive risk management. However, the resolution of the ChemFrance dispute through the MAP process also demonstrates that effective remedies exist for companies that are willing to pursue them through the appropriate channels. The key lessons are the importance of contemporaneous documentation prepared with Chinese-specific comparables, the need for ongoing technology contributions that can be documented and defended in audit, the value of the MAP mechanism as a dispute resolution forum, and the desirability of structuring licensing agreements with built-in flexibility to adjust royalty terms as technology and market conditions evolve.